LYPD3/C4.4A Recombinant Rabbit mAb (S-R222),Starter_specification/price/image

Product Detail
Company Profile

Product Specification

Host	Rabbit
Antigen	LYPD3/C4.4A
Synonyms	Ly6/PLAUR domain-containing protein 3, GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein (MIG-C4)
Location	Cell membrane
Accession	O95274
Clone Number	S-R222
Antibody Type	Recombinant mAb
Application	WB, IHC-P, FCM, IP
Reactivity	Hu
Purification	Protein A
Concentration	0.5 mg/ml
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS, 40% Glycerol, 0.05%BSA, 0.03% Proclin 300
Stability & Storage	12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution

application	dilution	species
WB	1:1000	null
IP	1:50	null
IHC	1:2000	null
FCM	1:500	null

Background

C4.4A (Ly6/PLAUR domain-containing protein 3, LYPD3), first reported in 1998, is a tumorigenic and high-glycosylated cell surface protein that has been proven to be linked with the carcinogenic effects in different solid tumors. The elevated expression of LYPD3 is not only demonstrated to be associated with lung adenocarcinoma carcinogenesis and poor prognosis but also there is evidence that LYPD3 can lead to the initiation and development of cancers and the chemoresistance of metastatic cancers by impacting the proliferation and apoptosis of the tumor, which are involved in many important regulatory mechanisms of cancers.

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.